Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
- Conditions
- Friedreich Ataxia
- Registration Number
- NCT06016946
- Lead Sponsor
- Friedreich's Ataxia Research Alliance
- Brief Summary
This project is a global, multicenter, prospective, longitudinal, observational natural history study that can be used to understand the disease progression and support the development of safe and effective drugs and biological products for Friedreich ataxia.
- Detailed Description
The UNIFAI Study: Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study is a global research study designed to provide a deep and evolving understanding of the natural history of this rare and debilitating genetic disorder as well as inform clinical trial design and implementation.
Friedreich's Ataxia is a rare, inherited, multi-system condition characterized by progressive neurological and cardiac symptoms. It is caused by mutations in the FXN (frataxin) gene.
The UNIFAI study is a multicenter, prospective, longitudinal, observational study, which means that all data about the natural disease course will be captured at study visits conducted annually according to a single protocol for all sites. This study will recruit participants with FA worldwide, to be assessed annually for up to 25 years. Study participation involves yearly study visits with data collected from medical records and history along with clinical outcome assessments including, neurological exams, timed walking tests, upper limb function measures, and patient-reported quality of life assessments, with the option for sites to collect additional ancillary measures related to speech, vision, fatigue, balance and cognition.
This global study is a harmonization of two well-established, long-standing natural history studies in FA that have provided a framework for further investigation of clinical measures that can quantitatively assess FA: FACOMS (US, Canada, Australia, New Zealand, and India) and EFACTS (European countries). These studies have been conducted in parallel with many similarities in study conduct. Uniting these two existing studies and groups of researchers gives greater power to data previously collected as well as future data. It also continues efforts to expand the network of clinical research centers specializing in FA called the FA-Global Clinical Consortium.
Due to advances in understanding the genetic and cellular dysfunction of FA that lead to symptoms observed in affected individuals, there has been significant growth in the discovery and development of therapeutic approaches, many currently being evaluated in clinical trials and a first approved treatment in the United States in 2023. The UNIFAI study aims to build upon this momentum by focusing on several key objectives.
UNIFAI will assess the natural history of FA by collecting data from diagnosed individuals of all ages and stages of disease progression. The data collected includes demographics, medical history, medications, neurological and functional assessments, cardiac examinations, laboratory studies, and health questionnaires. The study will assess and evaluate clinical outcomes in individuals with FA, such as disease progression, symptom severity, and overall quality of life, by various factors that might influence such outcomes such as genetic mutation, demographics (age, geography), co-existing conditions, medications, or treatments. By tracking outcomes over time, researchers aim to discern patterns, trends, and potential variations in subgroups or in the effectiveness of therapies or interventions across a diverse group of participants.
The UNIFAI study aims to play a pivotal role in identifying clinical milestones and changes in natural history over time as new treatments emerge. The study will monitor how these interventions alter the trajectory of the disease, potentially leading to the identification of crucial tipping points, disease landmarks, or stages where interventions can be most impactful. This study has the potential to significantly improve our understanding of FA and lead to more effective treatments and improved outcomes for those living with FA.
The study aims to inform clinical trial design and the development and validation of novel clinical outcome assessments and biomarkers that can be used in clinical trials. The UNIFAI study aims to capture data from a wide and diverse cohort of individuals with FA so that this dataset can be used to inform the selection of inclusion and exclusion criteria and power calculations for trial designs with specific clinical outcome measures.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 3000
-
Both males and females of any age
-
Individuals with Friedreich ataxia (FA): Participants that meet genetically confirmed diagnosis of Friedreich ataxia
-
Written informed consent provided
- Informed consent must be obtained for all participants
- For underage participants, they and the parent/ legally authorized representative have to sign the informed consent form, child assent (if applicable)
- Persons who are not legally competent require the informed consent of their legally authorized representative
- Unable or unwilling to provide informed consent
- Acute or ongoing medical or other conditions that would interfere with the conduct and assessments of the study
- For any reason in the opinion of the investigator, participant would be unlikely or unable to comply with study protocol requirements.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in FA Activities of Daily Living (ADL) Score Baseline, Year 1-25 The FARS-ADL is a subsection of the FARS questionnaire that assesses activities of daily living, including speech, personal hygiene, feeding, and mobility. Participants rank each category using a scale of 0 (normal) to 4 (severe disability/ inability to carry out activity independently), with lower scores indicative of "normal" function/activity. The score will be compared to the previous year annually for up to 25 years.
Change in Scale for the Assessment and Rating of Ataxia (SARA) Score Baseline, Year 1-25 The Scale for the Assessment and Rating of Ataxia (SARA) is a semi-quantitative assessment of ataxia, measuring ataxia of upper limb, lower limb, gait, balance and speech. It has eight items: gait, stance, sitting, speech disturbance, finger chase, nose-finger test, fast alternating hand movement, and heel-shin slide. The total score ranges from 0 (no ataxia) to 40 (severe ataxia). The score will be compared to the previous year annually for up to 25 years.
Change in Upright Stability (US) Score Baseline, Year 1-25 The Upright Stability (US) assessment is part of the neurological examination within the Modified Friedreich Ataxia Rating Scale (mFARS). This component comprises nine items: sitting position, stance with feet apart, stance with feet apart and eyes closed, stance with feet together, stance with feet together and eyes closed, tandem stance, stance with dominant foot, tandem walk, and gait. The score ranges from 0 to 9, with a higher score reflecting poorer upright stability (i.e., greater neurological severity). The score will be compared to the previous year annually for up to 25 years.
Change in modified Friedreich Ataxia Rating Scale (mFARS) Score Baseline, Year 1-25 The modified Friedreich Ataxia Rating Scale (mFARS) is a disease-specific scale that measures progression of neurological effects of FA. The mFARS is a validated and reliable scale; comprised of the neurologic component of the FARS and evaluates bulbar, upper limb, lower limb, and upright stability/gait function. For each item, responses categorize the corresponding neurological finding, and the findings are assigned a score ranging from 0 to 3, 4, or 5 with 0 being normal and higher numbers indicative of greater impairment. The score ranges from 0 to 93. The score will be compared to the previous year annually for up to 25 years.
- Secondary Outcome Measures
Name Time Method Change in Timed walk (25-foot or 8-meter) mean time (seconds) Baseline, Year 1-25 The timed 25-foot/8-meter walk examines upright stability, balance and mobility and involves walking a predetermined distance. Two consecutive trials are undertaken. The average time in seconds taken to complete the task, is calculated. The score will be compared to the previous year annually for up to 25 years.
Change in 9-hole peg test mean time (seconds) Baseline, Year 1-25 The 9 Hole Peg Test (9HPT) examines finger dexterity and involves placing and removing nine pegs in a pegboard in the quickest possible time. Two consecutive trials of the dominant hand, followed immediately by two consecutive trials of the non-dominant hand, are undertaken. The average time in seconds taken to complete the task, for each of the dominant and non-dominant hand, is calculated. The 9HPT has high intra- and inter-rater reliability and is the most commonly used measure of upper limb function in FA. The score will be compared to the previous year annually for up to 25 years.
Change in Speech analysis scores Baseline, Year 1-25 A battery of speech evaluations will be administered and recorded on a laptop for analysis, using Redenlab software. This will include: reading of a phonetically-balanced passage, sustained vowel sound, listing days of the week, repeating syllables, and a monologue task. This will form a measure of dysarthria. Redenlab is a US-Australian speech-testing company, https://redenlab.com. The score will be compared to the previous year annually for up to 25 years.
Change in Ataxia Instrumented Measures (AIMs)clinical severity score Baseline, Year 1-25 The Ataxia Instrumented Measures (AIMs) system consists of three components: 1) the data logger which is either a spoon, cup or pendant each containing sensors, Wi-Fi and processor; 2) algorithms that distinguishes between movements made by control and users with ataxia and grades the severity of ataxia when detected; and 3) ataxia scores presented in a manner that has utility for clinicians (the AIM "score"). This score is continuous and features an ataxia severity threshold which has been established through the process of machine learning and is based on the separation between individuals with ataxia and control participants. Any value below the severity threshold of a specific device is expected for controls/very mild ataxia, and any value beyond is expected for individuals with moderate/severe ataxia. The score will be compared to the previous year annually for up to 25 years.
Change in Lower Contrast Letter Acuity test score Baseline, Year 1-25 Contrast letter acuity for vision will be assessed using back-lit Low-Contrast Sloan Letter Charts (LCSLCs). Participants will sit at an eye distance of 2 metres from the chart. Binocular vision will be assessed using participants' normal corrective lenses where relevant. Participants are required to read each letter on the chart. Three charts will be presented, with three different visual contrast levels: 100% (equivalent to high-contrast visual acuity), 2.5%, and 1.25%. The maximum total score across the three charts (number of letters read correctly) is 240. Scores for each individual chart will also be recorded.
Trial Locations
- Locations (34)
UCLA Ataxia Center
🇺🇸Los Angeles, California, United States
University of Colorado
🇺🇸Denver, Colorado, United States
University of Florida - Neurology
🇺🇸Gainesville, Florida, United States
USF Ataxia Research Center
🇺🇸Tampa, Florida, United States
Emory University Hospital - Neurology
🇺🇸Atlanta, Georgia, United States
University of Iowa, Stead Family Children's Hospital
🇺🇸Iowa City, Iowa, United States
Ohio State University - Neurology
🇺🇸Columbus, Ohio, United States
Children's Hospital of Philadelphia
🇺🇸Philadelphia, Pennsylvania, United States
St. Jude Children's Research Hospital
🇺🇸Memphis, Tennessee, United States
Murdoch Childrens Research Institute
🇦🇺Parkville, Victoria, Australia
Medical University Innsbruck, Department of Neurology
🇦🇹Innsbruck, Austria
Université Libre de Bruxelles, Hôpital Erasme, Dpt of Neurology
🇧🇪Bruxelles, Belgium
University of Campinas
🇧🇷Campinas, Brazil
The Hospital for Sick Children
🇨🇦Toronto, Ontario, Canada
McGill University Health Centre - Montreal Neurological Institute
🇨🇦Montreal, Quebec, Canada
CHUM - Hopital Notre-Dame
🇨🇦Montréal, Quebec, Canada
Motol University Hospital, Centre for Hereditary Ataxias
🇨🇿Praha, Czechia
Paris Brain Institute
🇫🇷Paris, France
Hôpital de Hautepierre, Service de Neurologie
🇫🇷Strasbourg, France
University Hospital Aachen, Dept. of Neurology
🇩🇪Aachen, Germany
Deutsches Zentrum Für Neurodegenerative Erkrankungen
🇩🇪Bonn, Germany
University of Munich, Dept. of Neurology, Friedrich-Baur-Institut
🇩🇪Munich, Germany
University of Tübingen, Dept. of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research
🇩🇪Tübingen, Germany
National and Kapodistrian University of Athens, Neurogenetics Unit
🇬🇷Athens, Greece
All India Institute of Medical Sciences (AIIMS)
🇮🇳New Delhi, NCT, India
Tallaght University Hospital, Department of Neurology
🇮🇪Dublin, Ireland
Referente Clinico-Scientifico di Polo IRCCS "E. Medea"
🇮🇹Conegliano, Italy
Fondazione IRCCS Istituto Neurologico Carlo Besta
🇮🇹Milan, Italy
Bambino Gesù Children's Hospital, Department of Neurosciences
🇮🇹Roma, Italy
Stichting Radboud Universitair Medisch Centrum
🇳🇱Nijmegen, Netherlands
Auckland City Hospital
🇳🇿Auckland, New Zealand
Hospital Sant Joan de Déu, Servicio de Neurología
🇪🇸Barcelona, Spain
Hospital Universitario La Paz, Servicio de Neurologia
🇪🇸Madrid, Spain
University College of London, Ataxia Centre, National Hospital for Neurology and Neurosurgery
🇬🇧London, United Kingdom